FX-06 (Fibrin-Derived Peptide B?15-42) – High Purity Research Peptide

描述

FX-06 (CAS No. 88650-17-3), also known as Fibrin-derived peptide B?15-42, is a synthetic bioactive peptide fragment derived from the fibrin B? chain. As a short peptide of 28 amino acids, it has been structurally optimized to mimic natural fibrin degradation products while retaining biological activity relevant to endothelial function and vascular protection.

The compound has been extensively investigated for its vascular protective properties, specifically through its interaction with endothelial adhesion molecules. FX-06 is recognized for binding to vascular endothelial (VE)-cadherin, a key adhesion protein responsible for maintaining endothelial cell-to-cell junction integrity. By stabilizing these junctions, FX-06 helps regulate vascular permeability, prevents excessive plasma leakage, and reduces leukocyte infiltration during inflammatory and ischemic events.

With a verified purity of 99.98% and produced under GMP-certified conditions, FX-06 provides exceptional consistency and reproducibility in research applications. This high-grade manufacturing ensures suitability for academic laboratories, pharmaceutical preclinical studies, and translational research exploring vascular biology.

FX-06 is particularly valuable in research focused on ischemia/reperfusion injury, Dengue shock syndrome (DSS), and endothelial barrier dysfunction, where vascular leakage and immune overactivation are central pathological features.

Product Specifications

These specifications ensure FX-06 is delivered in a stable, high-quality format suitable for long-term laboratory storage and reproducible experimental use.

Mechanism of Action & Research Applications

FX-06 exerts its activity primarily through VE-cadherin binding, which stabilizes endothelial adherens junctions and reduces vascular permeability. This mechanism plays a crucial role in protecting endothelial integrity during conditions characterized by hypoxia, inflammation, or mechanical stress.

Key molecular effects include:

• Inhibition of leukocyte transmigration – prevents excessive infiltration of immune cells across the vascular endothelium, limiting inflammatory damage.

• Modulation of vascular signaling pathways – triggers VE-cadherin-mediated intracellular signaling cascades, contributing to cytoskeletal rearrangements and tight junction stability.

• Reduction of plasma leakage – By preventing endothelial barrier breakdown, FX-06 reduces vascular leakage associated with shock syndromes and ischemic injury.

• Anti-inflammatory effects – FX-06 helps mitigate pro-inflammatory signaling by reducing leukocyte-endothelium interactions.

Research Applications:

• Ischemia/Reperfusion Injury Studies – Investigating protective effects on tissues such as myocardium, brain, and kidney exposed to oxygen deprivation and subsequent reperfusion.

• Dengue Shock Syndrome (DSS) Models – Exploring  as a modulator of endothelial leakage during viral-induced vascular dysfunction.

• Endothelial Barrier Research – Studying junctional proteins, vascular permeability, and endothelial stabilization mechanisms.

• Sepsis and Systemic Inflammation – Understanding its potential role in controlling microvascular leakage during severe immune activation.

• Vascular Biology and Immunology –  serves as a molecular tool to explore endothelial-immune cell cross-talk.

Development & Research Background

FX-06 emerged from research into fibrin degradation products and their role in modulating vascular responses. The B?15-42 sequence was identified as a fragment with bioactive properties relevant to endothelial stabilization. Early studies revealed that this peptide could reduce ischemia/reperfusion-associated damage by minimizing vascular leakage and inflammation.

In preclinical models, demonstrated significant protection in myocardial infarction, cerebral ischemia, and renal ischemia, with evidence of reduced infarct size and improved tissue viability. The peptide was also studied in models of viral hemorrhagic syndromes, including Dengue, where endothelial leakage is a hallmark of severe disease.

Clinical research interest in FX-06 has included Phase I/II clinical studies, where its safety and potential therapeutic efficacy in ischemia/reperfusion injury were investigated. While not developed into a commercial pharmaceutical, FX-06 remains a valuable research tool compound, continuing to inform studies of vascular integrity, inflammation, and endothelial barrier function.

Because it is manufactured under GMP-compliant standards, FX-06 is widely trusted by academic groups and pharmaceutical research teams. Its reproducibility, high purity, and well-characterized activity profile make it one of the most reliable endothelial research peptides available.

Side Effects

In experimental models, FX-06 has been associated with several context-dependent biological effects:

• Alterations in endothelial signaling – While stabilizing endothelial junctions, FX-06 can modify cell signaling pathways, requiring careful interpretation of experimental outcomes.

• Immune modulation – Its ability to limit leukocyte transmigration may alter inflammatory responses in research models.

• Variable outcomes in tissue reperfusion – Protective effects are often dose-dependent and may vary with experimental conditions.

These effects are not side effects in the clinical sense but represent biological observations relevant to laboratory models. Researchers should carefully design studies and interpret data in light of FX-06’s mechanism of action.

Disclaimer

is supplied exclusively for laboratory research use. It is not intended for human consumption, medical, or veterinary applications.

Keywords

• FX-06 peptide

•  CAS 88650-17-3

• Fibrin-derived peptide B?15-42

•  research chemical

• GMP  supplier